Neos Therapeutics, Inc. (NEOS) Issues Earnings Results

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.22, Bloomberg Earnings reports. Neos Therapeutics had a negative return on equity of 551.26% and a negative net margin of 339.52%. The company had revenue of $6.70 million during the quarter.

Neos Therapeutics (NEOS) traded down $0.35 during trading on Friday, hitting $10.15. The stock had a trading volume of 1,098,772 shares, compared to its average volume of 1,185,080. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $13.15. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14.

COPYRIGHT VIOLATION NOTICE: “Neos Therapeutics, Inc. (NEOS) Issues Earnings Results” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/11/19/neos-therapeutics-inc-neos-issues-earnings-results-beats-expectations-by-0-22-eps.html.

An institutional investor recently raised its position in Neos Therapeutics stock. State Street Corp boosted its holdings in shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) by 29.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 316,855 shares of the company’s stock after buying an additional 72,395 shares during the period. State Street Corp owned approximately 1.16% of Neos Therapeutics worth $2,312,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 45.13% of the company’s stock.

Several equities research analysts recently commented on the company. Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 26th. Wells Fargo & Company set a $14.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Wednesday, October 18th. Finally, Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $14.00.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply